argenx SE
ARGX817.320USD
+5.140+0.63%
收盤 10/24, 16:00（美東）報價延遲15分鐘
49.99B總市值
39.04本益比TTM
關於 argenx SE 公司
argenx SE（前身爲 arGEN X BV）是一家總部位於荷蘭的生物製藥公司。該公司主要致力於利用其發現平臺 Simple Antibody 創建和開發用於治療嚴重自身免疫性疾病的差異化抗體療法產品線，該平臺利用了駱駝免疫系統的特點。該公司開發了一系列專注於癌症和自身免疫適應症的抗體療法產品線。它包括但不限於：Empasiprubart，一種針對 C2 的補體抑制劑，可阻斷經典和凝集素途徑的功能，同時保持替代途徑完好無損，ARGX-119 是一種 MuSK 受體拮抗劑，具有多種神經肌肉適應症的潛力。
argenx SE簡介
公司代碼ARGX
公司名稱argenx SE
上市日期Jul 10, 2014
CEOMr. Tim van Hauwermeiren
員工數量1599
證券類型Ordinary Share
年結日Jul 10
公司地址Laarderhoogtweg 25
城市AMSTERDAM
上市交易所Euronext Brussels
國家Netherlands
郵編1101 EB
電話31763030
網址https://www.argenx.com/
公司代碼ARGX
上市日期Jul 10, 2014
CEOMr. Tim van Hauwermeiren
argenx SE公司高管
名稱
名稱/職務
職務
持股
持股變動
Mr. Karl Gubitz
Mr. Karl Gubitz
Chief Financial Officer
Chief Financial Officer
500.00
--
Mrs. Camilla Sylvest
Mrs. Camilla Sylvest
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Tim van Hauwermeiren
Mr. Tim van Hauwermeiren
Chief Executive Officer, Co-Founder, Executive Director
Chief Executive Officer, Co-Founder, Executive Director
--
--
Dr. Ana Cespedes
Dr. Ana Cespedes
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Karen Massey
Ms. Karen Massey
Chief Operating Officer
Chief Operating Officer
--
--
Mrs. Andria Wilk
Mrs. Andria Wilk
Global Head of Quality
Global Head of Quality
--
--
Mr. Arjen Lemmen
Mr. Arjen Lemmen
Vice President - Corporate Development and Strategy
Vice President - Corporate Development and Strategy
--
--
Ms. Malini Moorthy
Ms. Malini Moorthy
General Counsel
General Counsel
--
--
Mr. Peter Ulrichts
Mr. Peter Ulrichts
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Peter K. M. Verhaeghe
Mr. Peter K. M. Verhaeghe
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Karl Gubitz
Mr. Karl Gubitz
Chief Financial Officer
Chief Financial Officer
500.00
--
Mrs. Camilla Sylvest
Mrs. Camilla Sylvest
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Tim van Hauwermeiren
Mr. Tim van Hauwermeiren
Chief Executive Officer, Co-Founder, Executive Director
Chief Executive Officer, Co-Founder, Executive Director
--
--
Dr. Ana Cespedes
Dr. Ana Cespedes
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Karen Massey
Ms. Karen Massey
Chief Operating Officer
Chief Operating Officer
--
--
Mrs. Andria Wilk
Mrs. Andria Wilk
Global Head of Quality
Global Head of Quality
--
--
收入明細
單位: USD更新時間: 10月6日 週一
單位: USD更新時間: 10月6日 週一
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
暫無數據
地區USD
名稱
營收
佔比
United States
1.90B
86.56%
Rest of the World
161.25M
7.36%
Japan
89.39M
4.08%
China
43.52M
1.99%
Netherlands
153.00K
0.01%
業務
地區
暫無數據
股東統計
更新時間: 11 小時前
更新時間: 11 小時前
持股股東
股東類型
持股股東
持股股東
佔比
Fidelity Management & Research Company LLC
8.52%
T. Rowe Price Associates, Inc.
6.69%
Janus Henderson Investors
4.19%
Artisan Partners Limited Partnership
3.84%
Capital World Investors
3.19%
其他
73.56%
持股股東
持股股東
佔比
Fidelity Management & Research Company LLC
8.52%
T. Rowe Price Associates, Inc.
6.69%
Janus Henderson Investors
4.19%
Artisan Partners Limited Partnership
3.84%
Capital World Investors
3.19%
其他
73.56%
股東類型
持股股東
佔比
Investment Advisor
31.17%
Investment Advisor/Hedge Fund
16.98%
Hedge Fund
5.02%
Research Firm
1.00%
Pension Fund
0.54%
Private Equity
0.39%
Bank and Trust
0.09%
其他
44.81%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
829
32.61M
53.31%
-4.28M
2025Q2
819
35.58M
58.18%
-2.01M
2025Q1
824
33.92M
55.61%
-3.84M
2024Q4
769
34.65M
57.94%
-3.60M
2024Q3
721
35.68M
59.67%
-2.04M
2024Q2
693
34.77M
58.16%
-2.15M
2024Q1
675
34.54M
58.16%
-754.92K
2023Q4
655
33.23M
56.14%
-574.05K
2023Q3
612
32.76M
56.24%
+237.83K
2023Q2
559
31.23M
55.80%
-1.48M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Fidelity Management & Research Company LLC
5.21M
8.52%
-251.10K
-4.59%
Jun 30, 2025
T. Rowe Price Associates, Inc.
4.09M
6.69%
-498.08K
-10.85%
Jun 30, 2025
Janus Henderson Investors
2.57M
4.19%
+422.32K
+19.71%
Jun 30, 2025
Artisan Partners Limited Partnership
2.35M
3.84%
-436.11K
-15.65%
Jun 30, 2025
Capital World Investors
1.95M
3.19%
+13.09K
+0.68%
Jun 30, 2025
Avoro Capital Advisors LLC
1.18M
1.92%
-60.18K
-4.87%
Jun 30, 2025
T. Rowe Price International Ltd
887.87K
1.45%
+93.47K
+11.77%
Jun 30, 2025
Citadel Advisors LLC
865.97K
1.42%
+314.03K
+56.90%
Jun 30, 2025
ClearBridge Investments, LLC
772.87K
1.26%
+108.50K
+16.33%
Jun 30, 2025
RTW Investments L.P.
673.50K
1.1%
--
--
Jun 30, 2025
查看更多
持股ETF
更新時間: 10月6日 週一
更新時間: 10月6日 週一
機構名稱
佔比
VanEck Biotech ETF
5.81%
iShares Neuroscience and Healthcare ETF
4.66%
First Trust NYSE Arca Biotechnology Index Fund
4.12%
Goldman Sachs Future Health Care Equity ETF
2.96%
iShares Biotechnology ETF
2.66%
PGIM Jennison International Opportunities ETF
2.63%
Janus Henderson US Sustainable Equity ETF
2.6%
Invesco Nasdaq Biotechnology ETF
2.29%
ProShares Ultra Nasdaq Biotechnology
2.29%
Tema Oncology ETF
1.96%
查看更多
VanEck Biotech ETF
佔比5.81%
iShares Neuroscience and Healthcare ETF
佔比4.66%
First Trust NYSE Arca Biotechnology Index Fund
佔比4.12%
Goldman Sachs Future Health Care Equity ETF
佔比2.96%
iShares Biotechnology ETF
佔比2.66%
PGIM Jennison International Opportunities ETF
佔比2.63%
Janus Henderson US Sustainable Equity ETF
佔比2.6%
Invesco Nasdaq Biotechnology ETF
佔比2.29%
ProShares Ultra Nasdaq Biotechnology
佔比2.29%
Tema Oncology ETF
佔比1.96%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
